AACR logo

More articles from Therapeutic Agents: Other: Poster Presentations - Proffered Abstracts

Abstract C170: The combination of statins and dipyridamole is effective preclinically in AML, MM, and breast cancer.
Aleksandra Pandyra, Paul Sobol, Sumaiya Sharmeen, Aaron Schimmer, Linda Penn

Molecular Cancer Therapeutics Nov 2011, 10 (11 Supplement) C170; DOI: 10.1158/1535-7163.TARG-11-C170
Abstract C169: Inhibition of SREBPs by fatostatin reduces glioblastoma cell proliferation and viability.
Mary Youssef, Felicia Reinitz, Timothy Cloughesy, Paul Mischel, Deliang Guo

Molecular Cancer Therapeutics Nov 2011, 10 (11 Supplement) C169; DOI: 10.1158/1535-7163.TARG-11-C169
Abstract C178: Synergistic activity of SR16388 with microtubule inhibitors against multiple cancer cell lines.
Wei Zhou, Joy Calaogan, Barbara Sato, Lidia Sambucetti

Molecular Cancer Therapeutics Nov 2011, 10 (11 Supplement) C178; DOI: 10.1158/1535-7163.TARG-11-C178
Abstract C168: Cancer-selective mitochondrial copper transport by elesclomol results in potent single agent efficacy in multiple tumor types.
Jim Sang, Masazumi Nagai, Chaohua Zhang, Donald Smith, Manuel Sequeira, Luisa Shin Ogawa, Josephine Ye, Yuan Liu, Takayo Inoue, Dan Zhou, Keizo Koya, Yumiko Wada

Molecular Cancer Therapeutics Nov 2011, 10 (11 Supplement) C168; DOI: 10.1158/1535-7163.TARG-11-C168
Abstract C175: JS-K, a nitric oxide-releasing anticancer prodrug with a broad spectrum of action.
Anna E. Maciag, Joseph E. Saavedra, Rahul S. Nandurdikar, Ryan J. Holland, Paul J. Shami, Lucy M. Anderson, Larry K. Keefer

Molecular Cancer Therapeutics Nov 2011, 10 (11 Supplement) C175; DOI: 10.1158/1535-7163.TARG-11-C175
Abstract C180: The effect of JS-K, a lead O²-arylated diazeniumdiolate anticancer agent, on the cellular glutathione status.
Ryan J. Holland, Anna E. Maciag, Luis G. Rodriguez, Joseph E. Saavedra, Larry K. Keffer, Paul J. Shami

Molecular Cancer Therapeutics Nov 2011, 10 (11 Supplement) C180; DOI: 10.1158/1535-7163.TARG-11-C180
Abstract C174: Integrated real-time photoacoustic diagnostic imaging and therapeutics of oral cancer cells via gold nanorod conjugate.
Ping-Ching Wu, Dar-Bin Shieh, Tsung-Lin Tsai

Molecular Cancer Therapeutics Nov 2011, 10 (11 Supplement) C174; DOI: 10.1158/1535-7163.TARG-11-C174
Abstract C179: Discovery of a series of novel PARP-1 inhibitors with potent in vitro and in vivo activity.
Sui Xiong Cai, Qingbing Xu, Lizhen Wu, Lijun Liu, Yangzhen Jiang, Qingli Bao, Guoxiang Wang, Xiuyan Zhang, Feng Yin, Chengyun Gu, Xiuhua Hu, Xiaozhu Wang, Sishun Kang, Shengzhi Chen, Ye Edward Tian

Molecular Cancer Therapeutics Nov 2011, 10 (11 Supplement) C179; DOI: 10.1158/1535-7163.TARG-11-C179
Abstract C177: Chemical-driven biological probing: Discovery of a novel antimetastatic drug.
Li Xu, Rebecca Farmer, Xiaoke Huang, Matias Valsecchi, Janet Pavese, Eric Voll, Margaret Biddle, Antoinette Nibbs, Sean Pruell, Michael Avram, Karl Scheidt, Raymond C. Bergan

Molecular Cancer Therapeutics Nov 2011, 10 (11 Supplement) C177; DOI: 10.1158/1535-7163.TARG-11-C177
Abstract C176: Activity of novel indolequinone inhibitors of thioredoxin reductase 1 in pancreatic and colon cancers and in melanomas. Signaling mechanisms underlying antiproliferative activity.
Chao Yan, Martyn Inman, Christopher Thompson, Kevin Quackenbush, Jaclyn Reinemann, Dan Chan, Zhiyong Zhang, Wells Messersmith, John Arcaroli, David Siegel, Christopher J. Moody, David Ross

Molecular Cancer Therapeutics Nov 2011, 10 (11 Supplement) C176; DOI: 10.1158/1535-7163.TARG-11-C176

Main menu

User menu

Search

More articles from Therapeutic Agents: Other: Poster Presentations - Proffered Abstracts

Pages

Articles

Info for

About MCT